Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May:68 Suppl 2:e28562.
doi: 10.1002/pbc.28562.

Pediatric classical Hodgkin lymphoma

Andrea C Lo  1 , Karin Dieckmann  2 , Tanja Pelz  3 , Eve Gallop-Evans  4 , Rita Engenhart-Cabillic  5 , Dirk Vordermark  3 , Kara M Kelly  6 , Cindy L Schwartz  7 , Louis S Constine  8 , Kenneth Roberts  9 , David Hodgson  10
Affiliations
Review

Pediatric classical Hodgkin lymphoma

Andrea C Lo et al. Pediatr Blood Cancer. 2021 May.

Abstract

Over the past century, classical Hodgkin lymphoma (HL) has been transformed from a uniformly fatal disease to one of the most curable cancers. Given the high cure rate, a major focus of classical HL management is reducing the use of radiation therapy (RT) and chemotherapy agents such as procarbazine and doxorubicin to minimize long-term toxicities. In both North America and Europe, an important philosophy in the management of classical HL is to guide the intensity of treatment according to the risk category of the disease. The main factors used for risk classification are tumor stage, bulk of disease, and the presence of B symptoms. Response to chemotherapy is an important factor guiding the utilization of RT in ongoing Children's Oncology Group (COG) and European Network Pediatric Hodgkin Lymphoma (EuroNet-PHL) trials. Both trial groups have transitioned to reduced RT volumes that target the highest risk sites using highly conformal techniques, along with standard or intensified chemotherapy regimens to improve outcomes in higher risk patients. However, given the potential acute toxicities of intensified chemotherapy, immunoregulatory drugs are being investigated in upcoming trials. The purpose of this review is to summarize current approaches to treating pediatric classical HL according to the COG and EuroNet-PHL.

Keywords: Hodgkin lymphoma; IMRT; chemotherapy; involved-site radiation therapy; proton therapy; radiation therapy; treatment response.

PubMed Disclaimer

References

REFERENCES

    1. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651-3658. https://doi.org/10.1200/JCO.2013.52.5410.
    1. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059. https://doi.org/10.1182/blood-2008-10-184143.
    1. Keller FG, Castellino SM, Chen L, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children's Oncology Group. Cancer. 2018;124(15):3210-3219. https://doi.org/10.1002/cncr.31519.
    1. Charpentier A-M, Friedman D, Wolden S, et al. Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric Hodgkin lymphoma: analysis of the Children's Oncology Group AHOD 0031 Trial. Int J Radiat Oncol Biol. 2016;96(5):943-950. https://doi.org/10.1016/j.ijrobp.2016.07.015.
    1. Zhou R, Ng A, Constine LS, et al. A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the childhood cancer survivor study and recent Children's Oncology Group Trials. Int J Radiat Oncol Biol. 2016:1-5. https://doi.org/10.1016/j.ijrobp.2016.01.053.

Substances

LinkOut - more resources